Albireo AB

The sponsor concentrates on developing therapeutic interventions for rare cholestatic liver diseases affecting pediatric populations. Research efforts target conditions characterized by impaired bile flow and accumulation of toxic bile acids, which can lead to progressive liver damage in children. The organization's clinical programs address intrahepatic cholestasis and related hepatic complications that manifest during infancy and early childhood.

• Progressive Familial Intrahepatic Cholestasis (PFIC)
• Alagille Syndrome
• Biliary Atresia
• Bile Acid Synthesis Disorders

The therapeutic approach focuses on modulating bile acid homeostasis and reducing the hepatotoxic effects of accumulated bile acids in pediatric patients with genetic and congenital liver disorders. Clinical investigations evaluate treatments designed to interrupt the enterohepatic circulation of bile acids, thereby alleviating pruritus and preventing progressive liver injury in children with these debilitating conditions.